Mon, Jan 26, 2015, 5:13 AM EST - U.S. Markets open in 4 hrs 17 mins


% | $
Quotes you view appear here for quick access.

BioMarin Pharmaceutical (BMRN) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Feb 27, 2004 8:00 AM Flag

    Deleted Message

    In the last few days investors saw the chance of doubling their capital by the time BMRN files NDA for Aryplase and Phenoptin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Given the very very high liklihood of positive Phase 3 data on Aryplase, the fact that BMRN has identified almost half of the 500 (they're over 1000 so there's upside) patients necessary to reach $100MM in sales for Aryplase, and the fact that Phenoptin is basically a re-egnineered version of an existing drug that has a boat load of clinical data - I don't get it.

      Also, just playing off the multiples of Aldurazyme and Aryplase sales combined, which by 2007-8 should gross to BMRN over $150-200MM, this baby is trading at grotesquely low levels. (w/o Phenoptin or Pheylase approved)

      Once we get into April/May and Aryplase news comes out along with Phenoptin trial results and the start of a P/2 trial later in the year, we'll be back above 10. Afterall above $10 is only a $650M market cap. Pretty reasonable if you ask me.

97.69+1.8400(+1.92%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.